MedDataX Logo

Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma

NCT02652715 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2019-11-15

No results posted yet for this study

Summary

This pilot clinical trial studies Salvia hispanica seed in reducing the risk of returning disease (recurrence) in patients with non-Hodgkin lymphoma. Functional foods, such as Salvia hispanica seed, has health benefits beyond basic nutrition by reducing disease risk and promoting optimal health. Salvia hispanica seed contains essential poly-unsaturated fatty acids, including omega 3 alpha linoleic acid and omega 6 linoleic acid; it also contains high levels of antioxidants and dietary soluble fiber. Salvia hispanica seed may raise omega-3 levels in the blood and/or change the bacterial populations that live in the digestive system and reduce the risk of disease recurrence in patients with non-Hodgkin lymphoma.

Conditions

  • Adult Nasal Type Extranodal NK/T-Cell Lymphoma
  • Adult T-Cell Leukemia/Lymphoma
  • Anaplastic Large Cell Lymphoma
  • Angioimmunoblastic T-Cell Lymphoma
  • B Lymphoblastic Leukemia/Lymphoma
  • Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Burkitt Leukemia
  • Central Nervous System Lymphoma
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Enteropathy-Associated T-Cell Lymphoma
  • Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
  • Grade 1 Follicular Lymphoma
  • Grade 2 Follicular Lymphoma
  • Grade 3 Follicular Lymphoma
  • Hepatosplenic T-Cell Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Mantle Cell Lymphoma
  • Mediastinal (Thymic) Large B-Cell Lymphoma
  • Mycosis Fungoides
  • Nasal Type Extranodal NK/T-Cell Lymphoma
  • Nodal Marginal Zone Lymphoma
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Post-Transplant Lymphoproliferative Disorder
  • Primary Cutaneous Anaplastic Large Cell Lymphoma
  • Primary Effusion Lymphoma
  • Sezary Syndrome
  • Splenic Marginal Zone Lymphoma
  • Subcutaneous Panniculitis-Like T-Cell Lymphoma
  • Systemic Anaplastic Large Cell Lymphoma
  • T Lymphoblastic Leukemia/Lymphoma
  • Transformed Recurrent Non-Hodgkin Lymphoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DIETARY_SUPPLEMENT

Salvia hispanica Seed

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Thomas Witzig · Mayo Clinic

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-19
Primary Completion
2018-12-21
Completion
2019-11-12

Countries

  • United States

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02652715 on ClinicalTrials.gov